oa Editorial

“Opportunities Multiply as they are Seized.” -Sun Tzu Current Gene Therapy was born with the XXI century, as a reviews journal for gene therapy, a relatively new field of biomedical sciences that was gaining in maturity and solidity. Gene therapy was the result of a progressive merging of several scientific disciplines; genetics, molecular biology, virology, immunology and the clinical research of various organs and tissues affected by genetic diseases. Gene therapy has progressively evolved to include areas of diseases that are not directly of genetic origin, such as cancer or infectious diseases. Gene therapy is now a diverse and dynamic domain embracing almost every disease and pathophysiological process. During its first 10 years, Current Gene Therapy reflected the evolution of gene therapy and also aimed at pointing towards new directions and objectives of the field that appeared as promising. During this time, Current Gene Therapy has increased its visibility and impact. This was largely due to the strength of gene therapy's achievements that despite drawbacks and obstacles has generated very significant basic scientific knowledge and some clinical successes. Future applications of gene therapy as well as translational and basic research in the field of gene therapy will likely continue to increase and Current Gene Therapy will be an attentive partner for all basic and clinical researchers in the field. The second major asset of the journal has been the very high scientific level of authors submitting manuscripts and of reviewers. Sincere acknowledgments to them all and an enthusiastic invitation for more years of work, together on Current Gene Therapy.